Welcome to our dedicated page for XOMA Royalty SEC filings (Ticker: XOMAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on XOMA Royalty's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into XOMA Royalty's regulatory disclosures and financial reporting.
XOMA Royalty Corp director Matthew D. Perry received a grant of 3,586 restricted stock units (RSUs) of common stock at no cost. Each RSU converts into one share and will vest in equal monthly installments over 12 months, contingent on his continued service. Following this equity award, he directly owns 27,426 shares of XOMA common stock.
Franklin Heather L reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Heather L. Franklin received a grant of 3,586 restricted stock units (RSUs) of common stock on May 21, 2026. The award was made at no cash cost per share as part of equity compensation. Each RSU represents the right to receive one share of XOMA common stock at settlement and will vest in equal monthly installments over 12 months, subject to her continued service with the company. Following this grant, Franklin directly owns 9,557 shares of common stock, reflecting a modest, routine increase in her equity stake through compensation rather than open‑market buying.
Kosacz Barbara reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director Barbara Kosacz received a grant of 3,586 restricted stock units (RSUs) of common stock. The RSUs were awarded at no cash cost per unit and will vest in equal monthly installments over 12 months, conditioned on her continued service to the company. Following this equity award, she holds 9,557 shares of common stock directly.
XOMA Royalty Corporation reported the results of its 2026 Annual Meeting of Stockholders. Shareholders approved an amendment and restatement of the 2010 Long Term Incentive and Stock Award Plan, adding 425,000 shares of common stock for equity awards and extending the plan’s term to March 16, 2036.
They also approved the 2026 Employee Stock Purchase Plan, making 500,000 shares available for employee purchases, and ratified Deloitte & Touche LLP as independent auditor. All director nominees were elected and the advisory vote on executive compensation passed. As part of a previously announced merger process, the board adopted bylaw amendments addressing Nevada controlling interest statutes and adding exclusive forum provisions.
XOMA Royalty Corp large shareholders affiliated with Biotechnology Value Fund converted Series X Convertible Preferred Stock into common stock. On May 14, 2026, entities in the reporting group converted a total of 5,003 shares of Series X Preferred into 5,003,000 shares of common stock at a $4.03 per share conversion price. After these conversions, the Form 4 shows only common stock positions, with the Series X Preferred balances reduced to zero for the reporting entities involved. The transactions are reported as exempt from short-swing profit rules under Rule 16b-6(b) and reflect changes in the form of ownership rather than open-market buying or selling.
BVF Partners and affiliated funds report a 43.3% stake in XOMA Royalty Corp following conversion of preferred shares. The group now beneficially owns 7,593,303 common shares, calculated using 12,541,030 shares outstanding as of May 7, 2026 plus 5,003,000 shares received in a "Series X Conversion."
On May 14, 2026 the reporting persons increased the Series X Beneficial Ownership Limitation to 45% and converted all their Series X Preferred Stock into common shares at a conversion price of $4.03 per share. BVF, BVF2, Trading Fund OS and managed accounts together invested roughly $44.1 million in the converted and other purchased shares.
XOMA Royalty Corporation filed an update on its pending acquisition by Ligand Pharmaceuticals. On May 16, 2026, XOMA Royalty, Ligand, Flex Merger Sub and a newly formed subsidiary, XOMA Royalty Holdings Corporation (HoldCo), entered into Amendment No. 1 to their Agreement and Plan of Merger, formally adding HoldCo as a party.
HoldCo is a wholly owned subsidiary created to implement a holding company reorganization under Nevada law before Merger Sub combines with HoldCo, which will then become a wholly owned subsidiary of Ligand. The filing emphasizes that detailed terms and potential impacts will be described in preliminary and definitive proxy statements that XOMA Royalty plans to file, and urges stockholders to review those materials before voting on the proposed acquisition.
XOMA Royalty Corp Schedule 13G: Woodline Partners reports passive ownership of 5.4% of Common Stock, representing 640,001 shares. The filing cites 11,915,730 shares outstanding as of March 25, 2026. The statement is signed by Erin Mullen on 05/15/2026.
XOMA Royalty Corporation reported Q1 2026 total income and revenues of $12.3 million, down from $15.9 million a year earlier as revenue from contracts with customers declined, partly offset by higher income from purchased receivables under the effective interest rate method.
Operating expenses rose to $12.8 million from $10.0 million, driven mainly by higher general and administrative costs and amortization of intangible assets, resulting in an operating loss of $0.5 million. Gains on acquisitions and investment income lifted net income to $4.5 million, compared with $2.4 million in Q1 2025. Basic earnings per share available to common stockholders were $0.18, with diluted earnings per share of $0.17.
XOMA ended the quarter with $138.7 million in cash, cash equivalents, and restricted cash and total assets of $271.9 million. Total liabilities were $159.0 million, including current and long-term debt of about $102.8 million, while stockholders’ equity increased to $92.9 million. Management concluded existing liquidity is sufficient to fund planned operations for at least one year.
Ligand Pharmaceuticals has filed a Schedule 13D after entering into a merger agreement to acquire XOMA Royalty Corporation. Through voting and support agreements, Ligand may be deemed to beneficially own 8,062,678 shares, or 47.0% of XOMA’s common stock on an as-converted basis.
Under the merger, each XOMA common share will be converted into the right to receive $39.00 in cash plus contingent value rights tied to a CVR Trust’s interest in RemainCo LLC. Series X preferred shares will receive equivalent consideration on an as-converted basis, and the issuer’s perpetual preferred stock will be redeemed with accrued and unpaid dividends before closing. The deal requires majority stockholder approval, antitrust clearance, completion of a holding company reorganization and a CVR spin structure, and carries a $40,000,000 termination fee for specified failure or superior proposal scenarios.